For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Amyndas Pharmaceuticals SA, which is committed to developing innovative therapeutics to treat complement-mediated disorders, announced today that its lead candidate, the C3 complement inhibitor ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the ...

In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P .01 for all). Specific ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

When told what to kill, the complement system deftly deals the final blows—helping the immune system purge away pathogens and infected cells. But in the nervous system, debate rages as to whether this ...

Amyndas Pharmaceuticals S.A. is pleased to announce today that the Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas' lead candidate AMY-101, ...

We all forget things, and sometimes it would be better if we did not. Normal forgetting occurs more frequently as we age, but more serious, progressive, retrograde forgetting, which can have severe, ...